Please ensure Javascript is enabled for purposes of website accessibility

Abbott's Coronavirus Antibody Test Proves Highly Accurate

By Jim Crumly - Updated May 8, 2020 at 5:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Researchers found the test correctly returned negative results 99.9% of the time and positive results 100% of the time.

Researchers from the University of Washington School of Medicine found that the blood test for SARS-CoV-2 antibodies recently launched by Abbott Laboratories (ABT 0.09%) is highly accurate in detecting antibodies in patients tested at least 17 days after the onset of symptoms. The results found the test has 99.9% specificity, or about one false positive out of a thousand healthy patients, and 100% sensitivity, or a complete lack of false negative results in patients confirmed to have had COVID-19.

The research was performed in Boise, Idaho, as part of an initiative called "Crush the Curve," sponsored by local businesses. The researchers tested 1,020 blood samples that were collected before COVID-19 arrived in the U.S. and found one false positive. They also tested 689 blood samples from 125 patients who had been confirmed to have COVID-19, and those tests returned positive results 100% of the time.

Test tube of blood labelled "COVID-19"

Image source: Getty Images.

Abbott launched the test for the SARS-CoV-2 IgG antibody for its Architect laboratory-based testing system on April 15, and it was granted emergency use authorization by the Food and Drug Administration on April 26. The test detects a specific protein the body produces in the late stages of a COVID-19 infection, one which may remain in the bloodstream for months and possibly years after the patient recovers. Scientists don't yet know if the antibody confers immunity to COVID-19, but widespread antibody testing is required in order for governments and the medical community to measure the prevalence and spread of the disease.

Abbott has already shipped 10 million antibody tests for its Architect platform and plans to ramp up production capacity to 20 million tests a month in June. The Crush the Curve Idaho initiative -- which only tests people who think they may have had COVID-19 and recovered -- has tested over 10,000 individuals in the Boise area, with 0.71% of them returning positive results.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$110.06 (0.09%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.